{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:36:18Z","timestamp":1757309778250,"version":"3.40.5"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Macular Diseases Foundation"},{"name":"National Health and Medical Research Council, Australia"},{"name":"Royal Australian New Zealand College of Ophthalmologists\u2019 Eye Foundation","award":["2007-2009"],"award-info":[{"award-number":["2007-2009"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Importance<\/jats:title><jats:p>To assess early outcomes of intravitreal vascular endothelial growth factor (VEGF) inhibitor treatment in neovascular age\u2010related macular degeneration (nAMD) before patients have a chance to miss or discontinue treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Intravitreal VEGF inhibitors used to treat nAMD have been compared in various ways. The present study compared the 4\u2010week responses to the first injection of either aflibercept, bevacizumab, or ranibizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Observational study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Treatment\u2010na\u00efve nAMD patients with visual acuity (VA) taken 22 to 48\u2009days after the first treatment with an intravitreal VEGF inhibitor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An observational study from a prospectively designed database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>VA change from baseline and proportion of eyes judged active 22 to 48\u2009days after the first treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall mean (95% confidence interval [CI]) VA change at 4\u2009weeks was +3.7 (3.3, 4.0) letters. No pairwise comparisons in crude VA change or VA change after multivariate adjustment between the three agents were significant. However, after multivariate adjustment, more eyes treated with bevacizumab (90%) had active disease 4\u2009weeks after the first injection than ranibizumab (84%; <jats:italic>P<\/jats:italic> =\u2009.013) and aflibercept (82%; <jats:italic>P<\/jats:italic> =\u2009.004). Older age, higher baseline vision and larger lesions were associated with lower VA change.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There was no significant difference in VA gains amongst all three drugs but ranibizumab and aflibercept seemed to be more efficacious in quelling disease activity 4\u2009weeks after the first treatment. VA change after the first injection was driven largely by baseline characteristics such as age, baseline VA and lesion size.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ceo.13798","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T13:13:13Z","timestamp":1590671593000},"page":"946-955","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Four\u2010week outcomes of vascular endothelial growth factor inhibitors for neovascular age\u2010related macular degeneration"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5891-7055","authenticated-orcid":false,"given":"Shaan","family":"Wiryasaputra","sequence":"first","affiliation":[{"name":"The Save Sight Institute, Sydney Medical School The University of Sydney  Sydney New South Wales Australia"},{"name":"Singapore National Eye Centre  Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-9803","authenticated-orcid":false,"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"The Save Sight Institute, Sydney Medical School The University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Marsden Eye Specialists  Parramatta New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Ferrier","sequence":"additional","affiliation":[{"name":"Gosford Eye Surgeons  Gosford New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hinchcliffe","sequence":"additional","affiliation":[{"name":"Tamworth Eye Centre  Tamworth New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"The Save Sight Institute, Sydney Medical School The University of Sydney  Sydney New South Wales Australia"},{"name":"University Hospital Zurich University of Zurich  Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C.","family":"Gillies","sequence":"additional","affiliation":[{"name":"The Save Sight Institute, Sydney Medical School The University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.6776"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00736.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318296b271"},{"volume-title":"R: A Language and Environmental for Statistical Computing","year":"2018","key":"e_1_2_8_8_1"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v067.i01"},{"key":"e_1_2_8_10_1","unstructured":"ChristensenRHB.Ordinal\u2014regression models for ordinal data. R Package Version2018.8\u201325."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.08.023"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.018"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.07.011"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.1019"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130396006"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00223-X"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00967-9"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4496"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.034"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002485"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fceo.13798","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.13798","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ceo.13798","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.13798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:04:32Z","timestamp":1693872272000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.13798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/ceo.13798"],"URL":"https:\/\/doi.org\/10.1111\/ceo.13798","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"type":"print","value":"1442-6404"},{"type":"electronic","value":"1442-9071"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"2020-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}